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Abstract: High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal
cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can
be toxic, causing capillary leakage syndrome and stimulating pro-tumor immune response. One of the
strategies to reduce the systemic toxicity of IL2 is the use ofmesenchymal stem cells (MSCs) as a vehicle
for the targeted delivery of IL2. Human adipose tissue-derivedMSCs were transduced with lentivirus
encoding IL2 (hADSCs-IL2) or blue fluorescent protein (BFP) (hADSCs-BFP). The proliferation,
immunophenotype, cytokine profile and ultrastructure of hADSCs-IL2 and hADSCs-BFP were
determined. The e↵ect of hADSCs on activation of peripheral blood mononuclear cells (PBMCs)
and proliferation and viability of SH-SY5Y neuroblastoma cells after co-culture with native hADSCs,
hADSCs-BFP or hADSCs-IL2 on plastic and Matrigel was evaluated. Ultrastructure and cytokine
production by hADSCs-IL2 showed modest changes in comparison with hADSCs and hADSCs-BFP.
Conditioned medium from hADSC-IL2 a↵ected tumor cell proliferation, increasing the proliferation
of SH-SY5Y cells and also increasing the number of late-activated T-cells, natural killer (NK) cells,
NKT-cells and activated T-killers. Conversely, hADSC-IL2 co-culture led to a decrease in SH-SY5Y
proliferation on plastic and Matrigel. These data show that hADSCs-IL2 can reduce SH-SY5Y
proliferation and activate PBMCs in vitro. However, IL2-mediated therapeutic e↵ects of hADSCs
could be o↵set by the increased expression of pro-oncogenes, as well as the natural ability of hADSCs
to promote the progression of some tumors.
Keywords: immunotherapy; mesenchymal stem cells; interleukin 2; cancer therapy; neuroblastoma
1. Introduction
Interleukin 2 (IL2) is one of the first cytokines which, along with interferon ↵ (IFN-↵), was used
for the treatment of cancer [1]. IL2 is mainly produced by CD4+ T-cells and plays a vital role in growth
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as well as di↵erentiation of T-cells, B cells, natural killer (NK) cells, and many other cell types [2]. It is
the ability of IL2 to stimulate the proliferation and activation of immune cells with antitumor activity
that made it possible to achieve successes in IL2-based immunotherapy of cancer [3]. High-dose (HD)
recombinant IL2 therapy has been shown to be e↵ective and has been approved by the Food and
Drug Administration (FDA) for the treatment of renal cell carcinoma and metastatic melanoma [4].
In the case of metastatic renal cell carcinoma, a complete response was observed in 7% of patients,
and a partial response was observed in 13% of patients. In the case of metastatic melanoma, 7% of
patients achieved a complete response [4]. However, after the therapy with recombinant IL2 was
approved by the FDA, it has been found that IL2 regulates not only e↵ector T-cells but also regulatory
T-cells (Tregs), which can inhibit an anti-tumor immune response [5,6]. In addition, the use of HD IL2
therapy can lead to increased vascular permeability, hypotension, pulmonary edema, hepatocyte cell
death and kidney failure [7]. Changing the way IL2 is administered from single HD to a subcutaneous
low-dose has been shown to prevent vascular permeability and hypotension [8]. However, since the
half-life of IL2 is a few minutes [9], the use of low-dose therapy does not allow a high concentration of
recombinant protein to be maintained during the treatment, which reduces therapeutic e cacy [10].
Interestingly, HD IL2-associated vessel toxicity can be used as a treatment for cancer [11]. Local
injection of IL2 in the tumor site induce disruption of tumor vessels only, science tumor blood vessels
are more vulnerable than normal blood vessels to the actions of IL2. At the same time, the dose of IL2
used for the local injection is too low to cause side e↵ects [12].
The use of mesenchymal stem cells (MSCs) may be a potential strategy that can reduce systemic
toxicity and ensure targeted delivery of IL2 as well as maintain high levels of IL2 in the tumor
microenvironment, since MSCs have the ability to migrate toward tumor sites in vivo [13–15]. The use
of MSCs for the delivery of chemotherapeutics, tumor suppressor proteins, cytokines, oncolytic viruses
andmicroRNAs (miRNAs) has previously been reviewed in detail [16–18]. Briefly, genetically modified
MSCs overexpressing cytokines/chemokines and other biological factors, have been shown to be
e↵ective in activating immune cells and suppressing a number of tumors in vitro and in vivo [19–22].
For example, MSCs expressing IFN-↵ were shown to induce cancer cell apoptosis in a metastatic
melanoma mouse model [19]. Similarly, genetically modified MSCs expressing tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) were shown to induce apoptosis in several tumor
types [23,24]. The antitumor activity of MSCs expressing various ILs has also been demonstrated.
For example, MSCs expressing IL12 increasedNK cell infiltration into tumors formed in amousemodel
of glioma [25], as well as decreasing metastasis and inducing cancer cell apoptosis in mice modelling
ovarian cancer [26]. In accordance with these findings, a recent study by You et al., showed that
amniotic fluid-derived MSCs expressing IL2 can induce ovarian cancer cell apoptosis in vivo [27].
However, development and implementation of MSC-based therapies have several potential
drawbacks. MSCs have been reported to support the progression of some tumor types, including head
and neck carcinoma [28], glioma [29], and breast cancer [30]. MSC-linked tumor progression is believed
to be mediated by growth factors secreted by MSCs, such as vascular endothelial growth factor (VEGF),
IL8, transforming growth factor   (TGF- ), epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF). In addition, MSCs in the tumor have the potential to di↵erentiate into pericytes
and tumor-associated fibroblasts (TAF), thereby promoting a tumorigenic microenvironment [31].
However, contrasting reports support a tumor suppressive role for MSCs in breast cancer [32],
Kaposi’s sarcoma [33] and pancreatic cancer [34], potentially through inhibition of the PI3K/AKT
pathway and activation of other pathways leading to cell-cycle arrest and apoptosis [35]. These data
suggest the e↵ect of MSCs on tumor growth and development depends on various molecules produced
by MSCs, however, the mechanisms of double-edged e↵ect of MSCs are yet to be fully understood.
To further address the challenges of using modified MSCs to treat tumors, we generated
a human adipose tissue-derived MSCs line (hADSCs) stably expressing IL2, to determine the e↵ects of
MSC-mediated IL2 delivery on SH-SY5Y neuroblastoma cell growth and immune modulation in vitro.
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2. Materials and Methods
2.1. Cells and Culture Conditions
Adipose tissue and blood samples were collected from donors at the Republican Clinical Hospital
in accordancewith approved ethical standards and current legislation (the protocolwas approved by the
Committee on Biomedical Ethics of Kazan Federal University (No. 3, 03/23/2017)). Informed consent
was obtained from each donor.
We isolated hADSCs from two di↵erent donors as previously described [36,37].
Briefly, subcutaneous adipose tissue samples were obtained during liposuction procedures.
Lipoaspirate was washed (3 ⇥ phosphate bu↵ered saline (PBS)) and fermented using 0.2% collagenase
(Biolot, St. Petersburg, Russia) at 37  C for 1 h. Erythrocytes were removed using Red Blood Cell
(RBC) Lysis Bu↵er (BioLegend, San Diego, CA, USA). The viability of the isolated cells was determined
using Trypan Blue Solution (0.4%, Gibco, Grand Island, NY, USA) staining. Cells were cultured in
Dulbecco’s modified Eagle medium (DMEM)/F12 medium (PanEco, Moscow, Russia) supplemented
with 10% fetal bovine serum (FBS, Invitrogen, Waltham, MA, USA), 2 mM L-glutamine and antibiotics
(100 U/mL penicillin, 100 µg/mL streptomycin, Biolot, St. Petersburg, Russia) and incubated at 37  C in
a humidified, 5% CO2 atmosphere. hADSCs were used up to passages 5–7.
Peripheral blood mononuclear cells (PBMCs) from two di↵erent donors were isolated using
Ficoll–Paque gradient fractionation as previously described [38]. Cells were cultured in RPMI-1640
medium (PanEco, Moscow, Russia) with 10% FBS (HyClone, Logan, UT, USA), 2 mM L-glutamine and
antibiotics (PanEco, Moscow, Russia) and incubated at 37  C, 5% CO2.
Human PC3 prostate cancer cells (ATCC #CRL-1435), SH-SY5Y bone marrow neuroblastoma
cells (ATCC #CRL-2266), A549 lung adenocarcinoma cells (ATCC #CCL-185) and 293T embryonic
kidney cells (ATCC #CRL-3216) were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Cells were cultured in DMEM/F12 medium (PanEco, Moscow, Russia) with 10%
FBS (HyClone, Logan, UT, USA), 2 mM L-glutamine and antibiotics (PanEco, Moscow, Russia) and
incubated at 37  C, 5% CO2. Subsequent passage of cells and medium replacement were carried out
according to standard protocols. Microscopy was done using an Axio Observer.Z1 (CarlZeiss, Jena,
Germany) microscope. Images were analyzed using the software Axio Vision Rel. 4.8.
2.2. Di↵erentiation of Mesenchymal Stem Cells (MSCs) into Adipocytes, Chondrocytes and Osteoblasts
Native and genetically modified hADSCs were di↵erentiated into adipogenic, chondrogenic
and osteogenic directions using StemPro® Adipogenesis Di↵erentiation Kit (#A10070-01), StemPro®
Chondrogenesis Di↵erentiation Kit (#A10071-01) and StemPro® Osteogenesis Di↵erentiation Kit
(#A10072-01), respectively (all Gibco, Grand Island, NY, USA) according to the manufacturer’s protocol.
For adipogenic di↵erentiation, hADSCs (1 ⇥ 104 cells) were seeded in a 24-well plate. When hADSCs
reached 70% confluence, culture medium was removed and di↵erentiation medium was added.
Di↵erentiation medium was replaced every three days for 14 days. To demonstrate adipogenic
di↵erentiation, cells were fixed (10% paraformaldehyde 10 min, room temperature (RT)) and stained
with 0.3% oil red O (#O0625, Sigma-Aldrich, St. Louis, MO, USA). For chondrogenic di↵erentiation,
hADSCs (5 ⇥ 104 cells in 5 µL) were seeded in the center of the well in 24-well plates and incubated
for 2 h in a high humidity chamber. At the end of the incubation, chondrogenesis media was added
and cells were incubated for 21 days. Chondrogenic di↵erentiation was determined by staining fixed
cells (10% paraformaldehyde 10 min, RT) with Alcian blue (1% in 0.1N HCl; #A5268, Sigma-Aldrich,
St. Louis, MO, USA). For osteogenic di↵erentiation, hADSCs (1 ⇥ 104 cells) were seeded in 24-well
plates. When hADSCs reached 70% confluence the culture medium was removed and di↵erentiation
medium was added. Di↵erentiation medium was replaced every three days for 28 days. Cells were
fixed with 10% paraformaldehyde for 10 min at RT and stained with 1% aqueous AgNO3 for 1 h
(in the dark) to determine the presence of calcium deposits.
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2.3. Lentivirus Production
Vector plasmid encoding human IL2 gene (pLX304-IL2) was obtained from the Harvard Plasmid
Database (#HsCD00421565-4). Vector plasmid pLenti CMV green fluorescent protein (GFP) Blast was
purchased fromAddgene, Watertown, MA, USA (#17445). Vector plasmid pLX303-BFP encoding a blue
fluorescent protein (BFP) gene was generated using Gateway cloning (Invitrogen, Waltham, MA, USA).
The BFP gene was sub-cloned from the donor vector (pDONR221) into the lentiviral plasmid vector
pLX303 by LR recombination using Gateway™ LR Clonase™ II Enzyme mix (#11791020, Invitrogen,
Waltham, MA, USA) according to the manufacturer’s instructions.
To produce the second-generation replication-incompetent lentiviruses (LVs), near confluent
293T cells were transfected using calcium phosphate with three plasmids’ encoding: target gene
vector; gag/pol genes and additional viral packaging genes (pCMV-dR8.2 dvpr, Addgene #8455,
Watertown, MA, USA); and glycoprotein G of the vesicular stomatitis virus gene (pCMV-VSV-G,
Addgene #8454, Watertown, MA, USA) [39]. Resulting LV-IL2, LV-BFP and LV-GFP were concentrated
by ultracentrifugation (2 h at 26,000 rpm). The viral titer was determined by infecting cells at various
dilutions of the viral stock and determining percentage of transduced cells by flow cytometry.
2.4. Genetic Modification and Selection
LV-IL2 or LV-BFPwere added at amultiplicity of infection (MOI) of 10 to hADSCs (50% confluency)
and cells were cultured with the virus in serum-free DMEM/F12 for 6 h. At the end of the incubation,
cells were washed and fresh complete DMEM/F12 medium was added. Selection was initiated 48 h
later by adding blasticidin S (5 µg/mL, Invitrogen, Waltham, MA, USA) for 10 days. To produce
SH-SY5Y cells expressing green fluorescent protein (GFP), 50% confluent SH-SY5Y cells were infected
with LV-GFP (MOI10) and cultured in serum-free DMEM/F12 for 6 h. Cells were washed and fresh
complete DMEM/F12 medium was added. Cells with GFP fluorescence were sorted using FACS Aria
III (BD Biosciences, San Jose, CA, USA).
2.5. Quantitative Polymerase Chain Reaction (qPCR)
Total RNA was extracted from hADSCs using TRIzol Reagent (Invitrogen, Waltham, MA, USA)
following the manufacturer’s instructions. Primers and probes specific to 18S ribosomal RNA (18S
rRNA), IL2, VEGF, matrix metalloproteinase 2 (MMP2) and TGF- 1 cDNAs were designed using
GenScript Online Real-time PCR (TaqMan) Primer Design Tool (GenScript, Piscataway, NJ, USA) and
synthesized by Lytech, Moscow, Russia) (Table 1).
Table 1. Primer and probe sequences of related genes for quantitative polymerase chain reaction (qPCR).
Target Gene Forward Primer (50 30) Reverse Primer (50 30) TaqMan Probe (50 30)
18S rRNA GCCGCTAGAGGTGAAATTCTTG CATTCTTGGCAAATGCTTTCG
[HEX]
ACCGGCGCAAGA
CGGACCAG [BH2]
IL2 CACCAGGATGCTCACATTTAAG GTCCCTGGGTCTTAAGTGAAAG
[FAM]
CCCAAGAAGGCCAC
AGAACTGAAACA
[BH1]
VEGF ATCACCATGCAGATTATGGC TGCATTCACATTTGTTGTGC
[FAM]
TCAAACCTCACC
AAGGCCAGCA [BH1]
MMP2 ACCCATTTACACCTACACCAAG TGTTTGCAGATCTCAGGGTC
[FAM]
TCAATGTCAGGAG
GCCCCATAGA [BH1]
TGF- 1 GCCTTTCCTGCTTCTCATGG TCCTTGCGGAAGTCAATGTAC [FAM] CCGACCCTGGACACCAACTAT [BH1]
hADSC RNA was used as a template for cDNA synthesis using reverse transcriptase (GoScript™
Reverse Transcription System (Promega, Madison, WI, USA)) according to manufacturer’s instructions.
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TaqMan-based qPCR was performed in MicroAmp 96 well plates (BioRad Laboratories, Hercules, CA,
USA) and contained 1 µL cDNA template, 0.3 µL of primers and probe mix (final primer concentration
of 300 nM each), 4.7 µL of MilliQ H2O and 4 µL of 10x TaqMan-bu↵er (Lytech, Moscow, Russia),
in a final volume of 10 µL. The qPCR was carried out in CFX96 Touch™ Real-Time PCR Detection
System (BioRad Laboratories, Hercules, CA, USA) following the protocol: pre-denaturation at 95  C for
3 min; 45 cycles of denaturation at 95  C for 10 s, and annealing at 55  C for 30 s. The gene expression
levels were normalized to 18S rRNA levels. Relative quantification was performed by the comparative
threshold cycle (DDCT) method.
2.6. Immunofluorescence
To analyze IL2 protein expression in native hADSCs and hADSCs-IL2 an immunofluorescence
assay was carried out. For this, 1 ⇥ 103 native hADSCs and hADSCs-IL2 were seeded on 24-well plate
in 400 µL of DMEM/F12. After 24 h, culture medium was removed and cells were fixed with 250 µL of
cold methanol for 10 min at RT. Fixed cells were washed 3 times for 5 min each in Tris-bu↵ered saline
(TBS; 50 mm Tris, 150 mm NaCl, pH 7.6). Then cells were incubated with primary anti-IL2 antibodies
(ab180780, Abcam, 1:100 dilution in TBS) for 1 h at RT. After that cells were washed 3 times for 5 min
in TBS and then incubated with secondary antibodies (Goat anti-Rabbit IgG (P & L) Fluorescei (Goat
anti-Rabbit IgG (P & L) Fluorescein, #A102FN, American Qualex, San Clemente, CA, USA 1:1000
dilution in TBS) for 1 h at RT. After washing three times for 5 min in TBS, cells were stained with
DAPI fluorescent dye (40, 6-diamidino-2-phenylindole; dilution 1:50,000 in TBS; Invitrogen, Waltham,
MA, USA) for 5 min, and washed again. Coverslips were mounted on the slides with a mounting
medium (ImmunoHistoMount, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The samples were
investigated under a LSM 780 confocal microscope (Carl Zeiss, Jena, Germany) using Zen black 2012
software (Carl Zeiss, Jena, Germany). All samples were imaged in the z-plane using identical confocal
settings (laser intensity, gain, and o↵set).
2.7. Western Blot Analysis
Whole cell (1 ⇥ 106 cells per extraction) protein lysates were prepared in RIPA bu↵er containing
Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Waltham, MA, USA).
Equal volumes of lysates were electrophoresed on 4–12% sodium dodecyl-sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) gradient gels and transferred onto 0.2 µm nitrocellulose membranes
(#162-0112, BioRad Laboratories, Hercules, CA, USA) using the trans-blot semi-dry electrophoretic cell
transfer system (BioRad Laboratories, Hercules, CA, USA). Membranes were stained overnight at 4  C
with rabbit polyclonal anti-IL2 primary antibody (1:200; #ab180780, Abcam, USA), rabbit polyclonal
anti-TGF- 1 (1:200; #sc-130348, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse polyclonal
anti-VEGF primary antibody (#sc-7269, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse
polyclonal anti-MMP2 primary antibody (#sc-13594, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or anti- -actin horseradish peroxidase (HRP)-conjugated antibody (1:1000; #A00730, GenScript,
Piscataway, NJ, USA) followed by HRP-conjugated goat anti-rabbit immunoglobulin G (1:2000;
#8a0467j, American Qualex Antibodies, San Clemente, CA, USA) or HRP-conjugated goat anti-mouse
immunoglobulin G (A3682, Sigma-Aldrich, St. Louis, MO, USA) for 2 h at RT. Proteins were
visualized with Clarity™Western ECL Substrate (#1705061, BioRad Laboratories, Hercules, CA, USA)
on a ChemiDoc XRS+ system (BioRad Laboratories, Hercules, CA, USA). The target protein signal
intensity was normalised against the housekeeping protein  -actin and relative levels of signal intensity
quantified using Image LabTM, version 6.0.1 (Bio-Rad Laboratories, Hercules, CA, USA).
2.8. Immunophenotyping
Immune phenotyping of hADSCs was undertaken using antibodies to: CD90 (FITC) (#555595,
BD Biosciences, San Jose, CA), CD29 (APC) (#303008, BioLegend, San Diego, CA, USA), CD166 (PE)
(#343904, BioLegend), CD44 (PE) (#103024, BioLegend, San Diego, CA, USA), CD73 (APC) (#344006,
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BioLegend, San Diego, CA, USA), and a negative control (PE) (BD StemflowTM Human MSC Analysis
Kit, BD Biosciences, San Jose, CA, USA) including antibodies to CD34, CD11b, CD19, CD45, and
HLA-DR. Native hADSCs, hADSCs-BFP and hADSCs-IL2 were trypsinized and washed (2⇥ PBS).
Cell aliquots (1 ⇥ 105 cells/mL) were incubated with appropriate antibodies for 30 min protected from
light at room temperature. Cells were washed once with PBS and analyzed by flow cytometry using
FACS Aria III (BD Biosciences, San Jose, CA, USA) and data analyzed using BD FACSDiva™ software
version 7.0.
2.9. Conditioned Medium Collection
Native hADSCs, hADSCs-BFP and hADSCs-IL2 were seeded at a density of 2 ⇥ 105 cells in
T75 culture flasks. Conditioned medium (CM) was harvested after 24, 48 and 72 h of cultivation,
centrifuged (1500 rpm for 5 min at room temperature) and stored at  80  C.
2.10. Cell Proliferation Assays
To analyze hADSC proliferation, cells were collected at a density of 70–80% confluence,
resuspended in DMEM/F12 medium, and then plated at a concentration of 5 ⇥ 103 cells in 100 µL of
medium per well of a 96-well culture plate and incubated for 24 and 48 h.
To analyze SH-SY5Y, A549 or PC3 proliferation cells were plated at a concentration of 5 ⇥ 103 cells
in 100 µL of DMEM/F12 medium in a 96-well plate. Cells were incubated for 24 h at 37  C, 5% CO2,
the medium was replaced with CM (various dilutions) harvested from the hADSCs at various time
points (total volume 100 µL per well) and incubated for 48 h. Proliferation of hADSCs or cancer
cells was evaluated using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit
(Promega, Madison, WI, USA) following the manufacturer’s instructions. The absorbance in the wells
was determined using an Infinite M200Pro (Tecan Trading AG, Mannedorf, Switzerland) reader in
a two-wave mode at 490 nm (main) and 630 nm (reference) wavelengths. Two biological replicates
were completed for all samples.
2.11. Transmission Electron Microscopy
Native hADSCs, hADSCs-BFP and hADSCs-IL2 were fixed in 2.5% glutaraldehyde in PBS for
24 h at 4  C. Post-fixation, cells were treated with 1% osmium tetroxide for 2 h and subsequently
dehydrated using ethanol at 30 to 96% v/v concentrations, acetone and then a final treatment in
propylene oxide before embedding in Epon 812 resin. After resin polymerization at 37, 45, and 60  C,
samples were cut into ultrathin sections using ultramicrotome (Leica UC7, Leica Biosystems, Wetzlar,
Germany). Sections were mounted on copper grids (Sigma-Aldrich, St. Louis, MO, USA, 200 mesh)
and contrast agents uranyl acetate and lead citrate were added. Ultrathin sections were examined
using a transmission electron microscope (TEM) HT7700 (Hitachi, Tokyo, Japan) at 100 kV.
2.12. Cytokine Multiplex Analysis
The Human Chemokine 40-plex Panel (#171ak99mr2, BioRad Laboratories, Hercules, CA,
USA) was used to analyze CM samples according to the manufacturer’s recommendations.
Human Chemokine 40-plex Panel detects CCL21, CXCL13, CCL27, CXCL5, CCL11, CCL24, CCL26,
CX3CL1, CXCL6, GM-CSF, CXCL1, CXCL2, CCL1, IFN-U, IL1 , IL2, IL4, IL6, IL8/CXCL8, IL10, IL16,
IP10/CXCL10, I-TAC/CXCL11,MCP-1/CCL2,MCP-2/CCL8,MCP-3/CCL7,MCP-4/CCL13,MDC/CCL22,
MIF, MIG/CXCL9, MIP-1↵/CCL3, MIP-1 /CCL15, MIP-3↵/CCL20, MIP-3 /CCL19, MPIF-1/CCL23,
SCYB16/CXCL16, SDF-1↵+ /CXCL12, TARC/CCL17, TECK/CCL25, TNF-↵. Fifty microliters of each
sample was used to determine cytokine concentration and the collected data was analyzed using
a Luminex 200 analyzer with MasterPlex CT control and QT analysis software (MiraiBio division of
Hitachi Software San Francisco, CA, USA). Each Bioplex analysis was conducted in triplicate for two
biological replicates.
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2.13. Peripheral Blood Mononuclear Cell (PBMC) Activation
PBMCs were plated in 35 mm non-treated dishes (2 ⇥ 106 cells per dish) in 2 mL of CM harvested
from hADSCs-IL2, native hADSCs or fresh DMEM/F12. Activation of PBMCs populations was
determined at 72 h by flow cytometry using FACS Aria III (BD Biosciences, San Jose, CA, USA),
a minimum of 20,000 events were acquired for each sample. The following populations of the
immune cells were investigated: late-activated T-cells (CD3+, HLA-DR+), activated CD8+ T-cells
(CD8+, CD38+), early-activated T-cells (CD3+, CD25+), NK cells (CD3 , CD56+), NKT-cells (CD3+,
CD56+). PBMCs were washed twice with PBS and resuspended at 1 ⇥ 105 cells/mL in PBS before being
incubated with antibodies for 30 min in the dark at RT. All samples were stained with allophycocyanin
(APC)-conjugated anti-human CD3 (#300312, BioLegend, San Diego, CA, USA) or Alexa Fluor
488-conjugated anti-human CD3 (#2324020, Sony Biotechnology, San Jose, CA, USA), Alexa Fluor
488-conjugated HLA-DR (#IM0463U, Beckman Coulter, USA), Alexa Fluor 647-conjugated anti-human
CD56 (NCAM) (#2191564, BioLegend, San Diego, CA, USA), R-phycoerythrin (PE)-Cy7-conjugated
anti-human CD25 (#2113060, Sony Biotechnology, San Jose, CA, USA), PE-conjugated anti-human
CD8a (#300908, BioLegend, San Diego, CA, USA) and Alexa Fluor 488-conjugated anti-human CD38
(#2117515, Sony Biotechnology, San Jose, CA, USA).
2.14. Co-Culture of Cancer Cells and Human Adipose Tissue-Derived Mesenchymal Stem Cells (hADSCs)
on Plastic
SH-SY5Y cancer cells were seeded together with native hADSCs, hADSCs-BFP or hADSCs-IL2
at a 1:1 ratio (using 5 ⇥ 103 cells of each cell type per well) in 96-well plate, 6 replicates of each
combination were used [40]. Cells were co-cultured in DMEM/F12 medium for 72 h. Cell proliferation
was determined using CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega,
Madison, WI, USA) as previously described [41].
Apoptosis and necrosis of SH-SY5Y-GFP after co-culture with native hADSCs, hADSCs-BFP or
hADSCs-IL2 were analyzed using 5 ⇥ 104 cells arrayed in triplicate in 6-well plates. After 72 h of
co-culture, SH-SY5Y-GFP cells were separated from native hADSCs, hADSCs-BFP or hADSCs-IL2 using
a FACSAria III (BD Biosciences, San Jose, CA, USA). After separation, 5⇥ 104 sorted SH-SY5Y cells were
immediately stained to detect apoptosis and necrosis using an APC Annexin V Apoptosis Detection Kit
with PI (#3804660, Sony Biotechnology, San Jose, CA, USA) according to the manufacturer’s protocol.
Stained cells were analyzed by flow cytometry using a FACS Aria III (BD Biosciences, San Jose, CA,
USA), a minimum of 15,000 events were acquired for each sample.
2.15. Co-Culture of Cancer Cells and hADSCs on Matrigel
Matrigel was thawed on ice, 200 µL of Matrigel (#356235, BD Biosciences, San Jose, CA, USA)
was placed into each compartment of a 12-well plate on ice, using cooled pipette tips. For Matrigel
polymerization, plates were incubated at 37  C for 30 min before seeding of the cells.
SH-SY5Y cells and hADSCs were labelled with DiO (green) and DiD (red) dyes, respectively,
using Vybrant Multicolor Cell-Labeling Kit (#V-22889, Invitrogen, Waltham, MA, USA) for general cell
membrane labelling, according to themanufacturer’s instructions. 5⇥ 105 hADSCs and2 ⇥ 106 SH-SY5Y
were resuspended in 500 µL of serum-free medium and stained with 2.5 µL of the corresponding dye.
hADSCs were incubated with dye for 15 min, SH-SY5Y were incubated with dye for 5 min at 37  C,
after which the cell suspension was centrifuged at 1500 rpm for 5 min and washed three times with
full DMEM/F12.
Stained cells were seeded on a Matrigel-coated 12-well plate in a 1:1 ratio (using 5 ⇥ 103 cells
of each cell type per well) in 1 mL of DMEM/F12. Self-organization of cancer cells and hADSCs in
co-culture was assessed within 120 h using phase-contrast and fluorescence microscopy with an Axio
Observer.Z1 inverted microscope (CarlZeiss, Jena, Germany) and Axio Vision software version 4.8.
Bioengineering 2020, 7, 59 8 of 27
2.16. Statistical Analysis
Statistical analysiswas achievedusingGraphPadPrism7 software (GraphPad Software, San Diego,
CA, USA), one-way analysis of variance (ANOVA) followed by Tukey honest significant di↵erence
(HSD) post-hoc comparisons test. Significant probability values are denoted as * p < 0.05, ** p < 0.01
and *** p < 0.001, **** p < 0.0001.
3. Results
3.1. hADSCs-IL2 Overexpress Interleukin 2 (IL2) mRNA and Protein and Retain a Mesenchymal Stem
Cell Phenotype
MSCs were isolated from adipose tissue and genetically modified with LV-IL2 (hADSCs-IL2) or
LV-BFP (hADSCs-BFP). Expression of IL2 gene mRNA was increased by 1000 times in hADSCs-IL2
compared to native hADSCs and hADSCs-BFP (Figure 1a). Overexpression of IL2 protein within
hADSCs-IL2 was confirmed by immunofluorescence assay and western blot analysis (Figure 1b,c).
Genetic modification failed to have a significant e↵ect on the proliferative activity of hADSCs-IL2
and hADSCs-BFP (Figure 1c). Immunofluorescence analysis of native hADSCs, hADSCs-BFP and
hADSCs-IL2 determined that the majority of native and genetically modified hADSCs shared the same
pattern of surface antigen expression, which was similar to that commonly detected on human MSCs.
The percentage of cells expressing these antigens in native hADSCs was as follows: CD29 98.8% ±
0.2%, CD44 99.6% ± 0.4% cells, CD73 55.3% ± 3.1%, CD90 55.4% ± 6.4%, and CD166 92.4% ± 4.8%.
Native hADSCs had a lower expression of the hematopoietic cell surface markers CD34, CD11b, CD19,
CD45, and HLA-DR (3.4% ± 1.1% positivity) (Figure 2); whilst hADSCs-IL2 expressed CD29, CD44,
CD73, CD90, CD166, in 98.1% ± 0.9%, 99.2% ± 0.8%, 46.7% ± 4.8%, 53.1% ± 3.4% and 94.7% ± 3.6% of
cells respectively. Similar to native hADSCs, hADSCs-IL2 were negative for hematopoietic cell surface
markers CD34, CD11b, CD19, CD45, and HLA-DR (0.8% ± 0.2% positivity) (Figure 2). hADSCs-BFP
expressed CD29, CD44, CD73, CD90, CD166, in 99.1% ± 0.9%, 99.3% ± 0.5%, 48.2% ± 3.7%, 55.1% ±
4.7% and 91.3% ± 5.1% of cells respectively. hADSCs-BFP were also negative for hematopoietic cell
surface markers CD34, CD11b, CD19, CD45, and HLA-DR (1.3% ± 0.8% positivity) (Figure 2a).
Like native hADSCs, the genetically modified hADSCs-IL2 maintained the ability to di↵erentiate
into adipogenic, osteogenic and chondrogenic lineages (Figure 2b). Together, these data indicate that
hADSCs-IL2 retain the phenotype of a mesenchymal stem cell, including the di↵erentiation properties
of this cell population.
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Figure 1. Detection of Interleukin 2 (IL-2) expression in human adipose tissue-derived MSCs were
transduced with lentivirus encoding IL2 (hADSCs-IL2). (a) Relative IL2 gene mRNA expression
determined by qPCR was increased by 1000 times in hADSCs-IL2. 18S RNA reference gene has been
used for normalization of the data. Bars represent the mean of two biological replicates with their
corresponding standard deviation (SD) (n = 3). (b) Expression of IL2 protein was confirmed using
immunofluorescence assay and (c) western blot analysis. (d) Relative proliferation of hADSCs 24- and
48-h post seeding in vitro was measured using a Cell Proliferation Assay kit (Promega, Madison, WI,
USA). Each value is presented as the % in relation to the control (native hADSCs) group. Bars represent
the mean ± SD (n = 6) of two biological replicates. **** p < 0.0001.
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were fixed and stained with Oil Red O. For osteogenic differentiation cells were cultured in 
reprogramming medium for 28 days. At day 28, cells were fixed and analysed by von Kossa staining. 
Chondrogenic differentiation was determined by staining with Alcian blue on day 21 after seeding 
Figure 2. Characterization of the native and genetically modified hADSCs. (a) Immunophenotype
of native and genetically modified hA SCs. hADSCs were stained with antibodies against specific
surface markers CD29, CD44, CD73, CD90, CD166 and neg tive cocktail (CD11b, CD19, CD34, CD45,
and HLA-DR. CD45) and analyzed by flow cytometry. Data are shown as the mean percentage ±
SD (n = 6) of two biological replicates. (b) Osteogenic, adipogenic and chondrogenic di↵erentiation
of hADSCs. Phase contrast microscope images. To di↵erentiate toward adipogenic lineage native
and IL2-genetically modified cells were cultured in reprogramming medium for 14 days. At day
14, cells were fixed and stained with Oil Red O. For osteogenic di↵erentiation cells were cultured in
reprogramming medium for 28 days. At day 28, cells were fixed and analysed by von Kossa staining.
Chondrogenic di↵erentiation was determined by staining with Alcian blue on day 21 after seeding
(adipogenic and osteogenic di↵erentiation: scale bar, 100 µm; chondrogenic di↵erentiation: scale bar,
200 µm).
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3.2. IL2 Expression A↵ects the hADSC Ultrastructure
Ultrastructure analysis of native hADSCs, hADSCs-BFP and hADSCs-IL2 was achieved using
TEM. In native hADSCs, the rough endoplasmic reticulum (ER) formed elongated cisterns with defined
ribosomes and medium electron dense internal contents (Figure 3a). Changes in the rough ER structure
were detected in all genetically modified cells (hADSCs-IL2 and hADSCs-BFP), with cells showing
a strong expansion of ER cisterns and irregular shape (round or oval). In addition, the rough ER
cisterns had a high electron dense content (Figure 3b,c). In some modified cells, ribosomes were
absent on the surface of the membrane cisterns of the ER and/or possessed rounded endosomes with
a high electron density in the cytoplasm (Figure 3d). In general, the cytoplasm of hADSCs-IL2 and
hADSCs-BFP had a high number of organelles, such as endosomes, ER, and the active Golgi complex
(GC) and a large number of outgoing vesicles and multivesicular bodies. The nuclei of these modified
cells also contained euchromatin and heterochromatin clusters near the wall, the karyolemma was
often blurred and nuclear pores were visible (Figure 3e).
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Figure 3. Ultrastructure analysis of native hADSCs, hADSCs-BFP (blue fluorescent protein) and
hADSCs-IL2 using transmission electron microscopy (TEM). (a) Rough endoplasmic reticulum (ER) of
native hADSCs had the form of elongated cisterns with well-distinguishable ribosomes and internal
contents of medium electron density (arrows). (b) Rough ER of hADSCs-BFP had high electron density
(arrows). (c) Rough ER of hADSCs-IL2 increased in size and had high electron density (arrows).
(d) hADSCs-IL2 contain an endosomes (arrows) in the cytoplasm. (e) Nuclear pores in hADSCs-IL2
karyolemma (arrow). N—nucleus. Scale bar: 1–2 µm.
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3.3. IL2 Overexpression Leads to a Modest Change in Cytokine Production
The levels of cytokines CX3CL1, CXCL6, IL8, CCL13, CCL15 and CCL20 were determined
in the CM of native hADSCs, hADSCs-BFP or hADSCs-IL2. CM levels of these cytokines were
reduced (1.5–2 times) in hADSCs-IL2 cultured over 72 h compared to native hADSCs and hADSCs-BFP
(Figure 4c). In addition to the above cytokines, changes in IL6 and IL8 secretion between the hADSC
groups were also determined. After 24 h of incubation, the level of secreted IL6 detected in the CM
was approximately the same across all hADSC groups (native hADSCs, hADSCs-BFP or hADSCs-IL2)
(Figure 4a). However, at 48 h and 72 h, IL6 levels in hADSCs-IL2 CM were significantly lower
(4535.2 ± 576.1 pg/mL and 27,925.7 ± 5796.7 pg/mL at 48 and 72 h respectively) than for native hADSCs
(12,142.9 ± 1675.6 pg/mL and 27,925.7 ± 5796.7 pg/mL) and hADSCs-BFP (9242.2 ± 21.7 pg/mL and
27,925.7 ± 5796.7 pg/mL) (Figure 4b,c). Like IL6, IL8 was also detected at relatively high levels in media
conditioned for 24 h, 11,666.5 ± 496.4 pg/mL in native hADSCs, 9857.5 ± 3.8 pg/mL in hADSCs-BFP
and 8209.6 ± 3563.2 pg/mL in hADSCs-IL2 (Figure 4a). However, in media conditioned for both
48, the concentration of secreted IL8 was decreased in hADSCs-BFP (3838.4 ± 7.6 pg/mL) and in
hADSCs-IL2 (1665.3 ± 453.2 pg/mL) compared to native hADSCs (11,314.3 ± 250.0 pg/mL) (Figure 4b).
Whilst the level of secreted IL8 decreased across all hADSC groups at 48 and 72 h when compared to
the levels detected at 24 h. The decreases seen in hADSCs-IL2 (1075.0 ± 10.0 pg/mL) was two-fold
lower compared to native hADSCs (2158.5 ± 104.6 pg/mL) and hADSCs-BFP (2038.1 ± 10.7 pg/mL) at
72 h (Figure 4c).
Bioengineering 2020, 7, x FOR PEER REVIEW 11 of 27 
density (arrows). (d) hADSCs-IL2 contain an endosomes (arrows) in the cytoplasm. (e) Nuclear pores 
in hADSCs-IL2 karyolemma (arrow). N—nucleus. Scale bar: 1–2 μm. 
3.3. IL2 Overexpression Leads to a Modest Change in Cytokine Production 
The levels of cytokines CX3CL1, CXCL6, IL8, CCL13, CCL15 and CCL20 were determined in 
the CM of native hADSCs, hADSCs-BFP or hADSCs-IL2. CM levels of these cytokines were reduced 
(1.5–2 times) in hADSCs-IL2 cultured over 72 h compared to native hADSCs and hADSCs-BFP 
(Figure 4c). In addition to the above cytokines, changes in IL6 and IL8 secretion between the hADSC 
groups were also determined. After 24 h of incubation, the level of secreted IL6 detected in the CM 
was approximately the same across all hADSC groups (native hADSCs, hADSCs-BFP or 
hADSCs-IL2) (Figure 4a). However, at 48 h and 72 h, IL6 levels in hADSCs-IL2 CM were 
significantly lower (4535.2 ± 576.1 pg/mL and 27925.7 ± 5796.7 pg/mL at 48 and 72 h respectively) 
than for native hADSCs (12142.9 ± 1675.6 pg/mL and 27925.7 ± 5796.7 pg/mL) and hADSCs-BFP 
(9242.2 ± 21.7 pg/mL and 27925.7 ± 5796.7 pg/mL) (Figure 4b,c). Like IL6, IL8 was also detected at 
relatively high levels in media conditioned for 24 h, 11666.5 ± 496.4 pg/mL in native hADSCs, 9857.5 
± 3.8 pg/mL in hADSCs-BFP and 8209.6 ± 3563.2 pg/mL in hADSCs-IL2 (Figure 4a). However, in 
media conditioned for both 48, the concentration of secreted IL8 was decreased in hADSCs-BFP 
(3838.4 ± 7.6 pg/mL) and in hADSCs-IL2 (1665.3 ± 453.2 pg/mL) compared to native hADSCs 
(11,314.3 ± 250.0 pg/mL) (Figure 4b). Whilst the level of secreted IL8 decreased across all hADSC 
groups at 48 and 72 h when compared to the levels detected at 24 h. The decreases seen in 
hADSCs-IL2 (1075.0 ± 10.0 pg/mL) was two-fold lower compared to native hADSCs (2158.5 ± 104.6 
pg/mL) and hADSCs-BFP (2038.1 ± 10.7 pg/mL) at 72 h (Figure 4c). 
 
Figure 4. Multiplex analysis of conditioned medium (CM) of native hADSCs, hADSCs-BFP and 
hADSCs-IL2. CM was harvested from native hADSCs, hADSCs-BFP, hADSCs-IL2 after 24 h of 
cultivation (a), 48 h of cultivation (b) and 72 h of cultivation (c). Fifty microliters of the sample were 
used for determining absolute cytokine concentration. Bioplex analysis was performed in two 
biological replicates, data are shown as the mean percentage ± SD (n = 3). 
Figure 4. Multiplex analysis of conditioned medium (CM) of native hADSCs, hADSCs-BFP and
hADSCs-IL2. CM was harvested from native hADSCs, hADSCs-BFP, hADSCs-IL2 after 24 h of
cultivation (a), 48 h of cultivation (b) and 72 h of cultivation (c). Fifty microliters of the sample were
used for determining absolute cytokine concentration. Bioplex analysis was performed in two biological
replicates, data are shown as the mean percentage ± SD (n = 3).
Finally, secretion of tumor necrosis factor ↵ (TNF-↵) was increased by 1.5-fold in hADSCs-IL2
(6.8 ± 0.2 pg/mL) compared to native hADSCs (4.7 ± 0.2 pg/mL) and hADSCs-BFP (4.6 ± 0.1 pg/mL)
after 72 h of cultivation (Figure 4c).
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3.4. hADSC-IL2 Conditioned Medium (CM) Can Stimulate the Proliferation of Tumor Cells
The e↵ect of the CM harvested from native hADSCs, hADSCs-BFP or hADSCs-IL2 on SH-SY5Y
(neuroblastoma), PC3 (prostate cancer) and A549 (lung adenocarcinoma) tumor cell proliferation
in vitro was investigated. CM was harvested after 24, 48 and 72 h of culture from native hADSCs,
hADSCs-BFP or hADSCs-IL2. Cancer cells were plated at a concentration of 5 ⇥ 103 cells/100 µL of
medium per well in a 96-well culture plate. After 24 h, the medium was replaced with CM from
native hADSCs, hADSCs-BFP or hADSCs-IL2 harvested at the 24, 48 or 72 h time points. CM was
either applied undiluted (100% CM) or at a 50:50 dilution of CM with DMEM/F12. Cancer cells were
grown in CM for 48 h before analysis of their proliferation activity. Growth of SH-SY5Y cells in
undiluted (100%) CM obtained from hADSCs-IL2 resulted in the increase in SH-SY5Y proliferation
by 65% when using 24-h CM (n = 6, p < 0.01), by 10% with 48-h CM (n = 6, p < 0.05) and 30% with
72-h CM (n = 6, p < 0.05) when compared to SH-SY5Y cells grown in CM obtained from hADSCs
and hADSCs-BFP across the same time points (Figure 5). The e↵ect of hADSCs-IL2 CM on PC3 cell
proliferation was more variable, showing decreased proliferation of PC3 cells by 13% when exposed
to media conditioned by hADSCs-IL2 for 24 h (n = 6, p < 0.01), but an increase in proliferation by
16% (n = 6, p < 0.01) when treated with media conditioned for 72-h, when compared to hADSCs and
hADSCs-BFP (Figure 5). CM had no significant e↵ect on A549 proliferative activity regardless of the
cells of origin. Interestingly, the proliferation of PC3 and A549 cells was greater when grown in fresh
DMEM/F12 alone than when exposed to CM from any hADSC group and/or time point. Only SH-SY5Y
cells demonstrated greater proliferation in CM, when media was conditioned by hADSCs-IL2 for 72 h
(Figure 5).
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Figure 5. Proliferative activity of SH-SY5 , 3 a A549 cancer cells after culturi g in CM from
hADSCs. SH-SY5Y, A549 or PC3 cells were plated at concentration 5 ⇥ 103 cells in 100 µL of
DMEM/F12 medium in 96-well plate. Cells were incubated for 24 h (37  C, 5% CO2), the medium
was replaced with CM (various dilutions) harvested from the hADSCs at various time points (total
volume 100 µL) and incubated for 48 h. Proliferation of hADSCs or cancer cells was evaluated using
the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI,
USA). CM 50—medium, containing 50% of Dulbecco’s modified Eagle medium (DMEM)/F12 and
50% of hADSC CM, total volume 100 µL. CM 100—100% hADSC CM, total volume–100 µL. Each box
represents the mean ± SD (n = 6) of two biological replicates. * p < 0.05, ** p < 0.01.
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3.5. hADSCs-IL2 Can Promote Angiogenesis and Increase Tumor Cell Invasion
It is known that MSCs are key participants of the tumor microenvironment and, in addition to
being able to suppress various tumor growth, they can promote tumor growth and metastasis, as well
as stimulate neovascularization by expressing multiple pro-angiogenic and trophic factors such as
VEGF, IL8, TGF- , EGF, and PDGF [17]. In this context, increased pro-oncogene expression in response
to further modifications of MSCs could cause a significant potential problem when using modified
MSCs for patient treatment. Therefore, we sought to determine the e↵ect of IL2 overexpression on
the abundance of VEGF,MMP2 and TGF- 1 genes, known to have pro-oncogenic and pro-angiogenic
properties [42–44] in hADSCs-IL2.
Using quantitative PCR of transcript levels, it was shown that, VEGF gene expression in
hADSCs-IL2 was increased 2.3-fold compared to native hADSCs (n = 3, p < 0.0001) and 1.5-fold
compared to hADSCs-BFP (n = 3, p < 0.0001) (Figure 6a). Similarly,MMP2 expression was increased
2.3-fold in the hADSCs-IL2 compared to native hADSCs (n = 3, p < 0.0001) and 1.5-fold compared
to hADSCs-BFP (n = 3, p < 0.0001) (Figure 6b). Finally, TGF- 1 gene expression was also confirmed
to increase in hADSCs-IL2, 1.6 and 1.2-fold compared to native hADSCs and hADSCs-BFP (n = 3,
p < 0.0001), respectively (Figure 6c). However, Western blot analysis of VEGF protein expression
showed that therewas no increase inVEGFprotein expression in hADSCs-IL2 compared to hADSCs-BFP
or native hADSCs (relative expression of 93%, 96% and 100%, respectively). The relative expression
of MMP2 protein was slightly increased (112%) in hADSCs-IL2 compared to hADSCs-BFP (108%)
and native hADSCs (100%). A slight increase could also be observed in TGF- 1 protein expression
in hADSCs-IL2 (114%) compared to hADSCs-BFP (106%) and native hADSCs (100%) (Figure 6a–c).
These data suggest that the over-expressed IL2 impacts the transcription and protein expression of
factors that modify the tumor microenvironment, such as MMP2 and TGF- 1. However, as in the case
of VEGF changes in transcription are not always seen at the protein level.
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3.6. hADSCs-IL2 Activates Mononuclear Blood Cells In Vitro
To determine if activation of PBMCs changes the expression of the leukocyte surface markers,
an analysis of a number of activation markers on human PBMCs was used to determine the
immunogenic e↵ects of hADSCs-IL2 on T and NK cells.
De novo expression of HLA-DR is characteristic for the late-activation stages (3–5 days) of
T-cells [45]. We found that 6.3 ± 0.4% of PBMCs cultured in the presence of hADSCs-IL2 CM express
CD3/HLA-DR which is typical for late T-cell activation. The percentage of CD3+/HLA-DR+ PBMCs
cultured in CM from native hADSCs and DMEM/F12 medium was significantly lower, 2.4 ± 0.3% and
2.8 ± 0.6%, respectively (n = 3, p < 0.01) (Figure 7a).
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cultivation in hADSCs and hADSCs-IL2 CM. PBMCs were plated in 35 mm non-treated dishes
(2 ⇥ 106 cells per dish) in 2 mL of CM harvested from hADSCs-IL2, native hADSCs or fresh DMEM/F12.
Activation of PBMCs populations was determined using flow cytometry after 72 h. (a) Number
of CD3+/HLA-DR+ late-activated T-cells, %. (b) Number of CD3+/CD25+ early-activated T-cells,
%. (c) Number of CD3+/CD56+ NKT-cells, %. (d) Number of CD8+/CD38+ activated T-killers, %.
(e) Dot-plotwith CD3 /CD56+NKcells cultured inDMEM/F12, hADSCCM, hADSCs-IL2CM. Each box
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CD25, ↵ subunit of IL2 receptor, is a marker of an early (12 h) T-cell activation [46]. The number of
CD3+/CD25+ cells was 7.1 ± 0.3% in PBMCs cultured in -IL2 CM, similar to the numbers found
when PBMCs were cultured in CM from native hADSCs or DMEM/F12 medium alone (6.9 ± 0.4% and
8.0 ± 0.5%, respectively) (Figure 7b).
Leukocytes expressing T-cell marker CD3 and theNK cell marker CD56, are identified asNKT-cells.
NKT-cells are cytotoxic against tumor cells and independent of T-cell receptor activation [47]. We have
shown that 3.0 ± 0.3% of PBMCs grown in CM from hADSCs-IL2 were positive for CD3/CD56 markers,
compared to just 1.3 ± 0.5% and 1.6 ± 0.4% of PBMCs incubated in CM from native hADSCs and
DMEM/F12 medium respectively (n = 3, p < 0.01) (Figure 7c).
CD38 expr ssion is associat d with late (1 day) activation and proliferatio of cytotoxic CD8+
T lymphocytes ( TLs) [45,48]. Analysis of the CD8+ and CD38+ exp ss on revealed that 33.4 ± 1.4% of
PBMCs expressed these receptors when cultured in hADSCs-IL2 CM. Significantly lower numbers of
CD8+/CD38+ cells were foundwhen PBMCswere cultured in CM from native hADSCs andDMEM/F12,
13.7 ± 1.8% and 12.4 ± 1.2%, respectively (n = 3, p < 0.01) (Figure 7d). These data confirm our previous
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observation that hADSCs-IL2 CM a↵ects the lymphocyte activation pattern, increasing the population
of late-activated T cells.
Expression of the neural cell adhesion molecule (NCAM), also known as CD56, in the absence
of CD3 is characteristic for NK cells. NK cells can be divided into two populations: CD56dim and
CD56bright NK cells [49]. We found that the number of CD56+/CD3  NK cells was higher in PBMCs
cultured in hADSCs-IL2 CM (8.8 ± 0.5%) compared to native hADSCs CM and DMEM/F12 (4.3 ± 0.7%
and 3.1 ± 0.3% respectively) (n = 3, p < 0.01) (Figure 7e). The majority of the NK cells cultured in
hADSCs-IL2 CM were CD56bright (72.5 ± 1.3% of the entire NK cell population), while the higher
proportion of CD56dim NK cells was found in PBMCs cultured in CM from native hADSCs and
DMEM/F12 (78.5 ± 0.7% and 70.0 ± 0.9% of the entire NK cell population, respectively) (Figure 7e).
3.7. Co-Culture of hADSCs-IL2 Reduces Proliferation and Mediates Apoptosis of SH-SY5Y
Our data demonstrate that CM harvested from hADSCs-IL2 increases SH-SY5Y cell proliferation.
However, cells can communicate by paracrine mechanisms or through direct cell–cell contact when
co-cultured. Therefore, we sought also to determine the e↵ect of the hADSC co-culture on survival
and proliferation of SH-SY5Y tumor cells. Neuroblastoma SH-SY5Y cells or SH-SY5Y-GFP cells were
co-cultured with native hADSCs, hADSCs-BFP or hADSCs-IL2 at a 1:1 ratio. Analysis of proliferative
activity demonstrated that co-culture of SH-SY5Ywith hADSCs-IL2 caused a significant decrease (~20%)
in cell proliferation (cumulative proliferation index of all cell populations in co-culture, 78.1 ± 7.9%)
compared to the co-culture of tumor cells with native hADSCs (100.0 ± 3.3%) or hADSCs-BFP
(107.7 ± 6.6%) (n = 6, p < 0.0001) (Figure 8a).
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proliferative activity of co-culture was determined using Cell Proliferation Assay kit (Promega, 
Madison, WI, USA). Each value is presented as the % in relation to the control (native hADSCs) 
group. Bars represent the mean ± SD (n = 6) of two biological replicates. (b,c) SH-SY5Y-GFP were 
co-cultured with native hADSCs, hADSCs-BFP and hADSCs-IL2. After 72 h of co-culture, 
SH-SY5Y-GFP cells were separated from native hADSCs, hADSCs-BFP or hADSCs-IL2 using FACS 
Figure 8. Analysis of SH-SY5Y cell proliferation and viability in co-culture with hADSCs. (a) SH-SY5Y
were co-cultured with native hADSCs, hADSCs-BFP and hADSCs-IL2 for 72 h and proliferative
activity of co-culture was determined using Cell Proliferation Assay kit (Promega, Madison, WI, USA).
Each value is presented as the % in relation to the control (native hADSCs) group. Bars represent
the mean ± SD (n = 6) of two biological replicat s. (b,c) SH-SY5Y-GFP were co-cultured with native
hADSCs, hADSCs-BFP and hADSCs-IL2. After 72 h of co-culture, SH-SY5Y-GFP cells were separated
from native hADSCs, hADSCs-BFP or hADSCs-IL2 using FACS Aria III (BD Biosciences, San Jose, CA,
USA). The apoptotic and necrotic cell counts were determined immediately after separation by Annexin
V/PI staining. Number of healthy (b), apoptotic (c) and necrotic (d) SH-SY5Y cells after co-cultivation
with hADSCs represents the mean ± SD (n = 3) of two biological replicates. * p < 0.05, ** p < 0.01,
**** p < 0.0001, ns: no significance.
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In addition to proliferation, tumor cell viability was determined by detection of apoptotic
and necrotic tumor cells. SH-SY5Y-GFP cells were separated from hADSCs using FACS (Aria III,
BD Biosciences, San Jose, CA, USA). Analysis of the number of apoptotic and necrotic SH-SY5Y
cells after co-culture with hADSCs-IL2 revealed a modest but significant decrease in cell viability
(percentage of non-apoptotic cells 86.3 ± 0.3%) compared to cells co-cultured with native hADSCs
(89.6 ± 1.1%) (n = 3, p < 0.05), however there was no significant di↵erence between hADSCs-IL2 and
hADSCs-BFP (86.2 ± 1.9%) (Figure 8b). The same results were observed for the number of apoptotic and
necrotic SH-SY5Y cells. The percentage of apoptotic SH-SY5Y cells, after co-culture with hADSCs-IL2,
was significantly increased (3.0 ± 0.4%), when compared to co-culture with native hADSCs (2.3 ± 0.1%)
(n = 3, p < 0.05), but there was no significant di↵erence between SH-SY5Y cells co-cultured with
hADSCs-IL2 and hADSCs-BFP (3.3 ± 0.1%) (Figure 8c). The percentage of necrotic SH-SY5Y cells,
when co-cultured with hADSCs-IL2, was significantly increased (3.2 ± 0.2%), in comparison with
co-culture with native hADSCs (2.3 ± 0.3%) (n = 3, p < 0.01), but there was no significant di↵erence
between SH-SY5Y cells co-cultured with hADSCs-IL2 and hADSCs-BFP cells (2.7 ± 0.2%) (Figure 8d).
In order to evaluate the organization and interaction of stem and tumor cells, native hADSCs,
hADSCs-BFP or hADSCs-IL2 and SH-SY5Y cells were co-cultured on the Matrigel matrix for 120 h.
After vital staining of hADSCs with Vybrant DiD dye and SH-SY5Y cells with Vybrant DiO dye,
all the cells had red or green fluorescence, respectively, which made it possible to distinguish these
cell types in co-culture. An interesting self-organization of hADSCs and SH-SY5Y in co-culture was
observed (Figure 9). After 48 h, the cells organized into individual cellular aggregates with flying
saucer-like architecture, in which the core consisted of hADSCs that were surrounded by flat aureole
of SH-SY5Y cells. Throughout the observation period, SH-SY5Y cells actively proliferated around
stem cells, the proliferation rate of tumor cells was significantly higher than the proliferation rate of
hADSCs, which led to the compression of hADSC cultures. It is interesting to note that in a co-culture
with hADSCs-IL2 the inhibition of SH-SY5Y tumor cell growth was clearly observed compared to
co-cultures of SH-SY5Y cells with native hADSCs or hADSCs-BFP (Figure 9).
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Figure 9. Analysis of the organization of SH-SY5Y and native and genetically modified hADSCs on
Matrigel matrix. SH-SY5Y cells and native hADSCs, hADSCs-BFP and hADSCs-IL2 were labelled
with DiO (green) and DiD (red) dyes using Vybrant Multicolor Cell-Labeling Kit and were co-cultured
for 120 h on a thin layer of Matrigel. Self-organization of cells in co-culture was evaluated after 48,
72, 96 and 120 h using phase-contrast and fluorescence microscopy with inverted Axio Observer.Z1
microscope. After 48 h, the cells organized into individual cellular aggregates with flying saucer-like
architecture, in which the cor consisted of hADSCs (r d) that were surrounded by a fl t aureole of
SH-SY5Y cells (green). Throughout the observation period, SH-SY5Y cells actively proliferated around
stem cells, the proliferation rate of tumor cells was significantly higher than the proliferation rate
of hADSCs, which led to the compression of hADSC cultures. In co-culture with hADSCs-IL2 the
inhibition of SH-SY5Y tumor cell growth was clearly observed compared to co-cultures of SH-SY5Y
cells with native hADSCs or hADSCs-BFP.
Bioengineering 2020, 7, 59 17 of 27
4. Discussion
The use of MSCs as a vehicle for the delivery of therapeutic agents can increase the e↵ectiveness of
IL2-based immunotherapy by stimulating an antitumor immune response or directly inhibiting tumor
growth. Our results showed that hADSCs-IL2 overexpressed both IL2 gene mRNA and IL2 protein.
At the same time, genetic modification did fail to have a significant e↵ect on the proliferative activity
and immunophenotype of hADSCs-IL2 and hADSCs-BFP compared to native hADSCs. Like native
hADSCs, the genetically modified hADSCs-IL2 were able to di↵erentiate into adipogenic, osteogenic
and chondrogenic lineages. However, overexpression of IL2 did cause significant changes in the
hADSCs-IL2 ultrastructure, where an increased size and density of rough ER, and the Golgi apparatus
were noted. However, significant changes in the ultrastructure of GC and ER in hADSCs-BFP were
also seen when compared to native hADSCs. Therefore, these changes may be linked to recombinant
protein overproduction rather than IL2 directly. Data produced by Hussain et al., demonstrate that
ER stress can occur in response to increased amounts of unfolded and misfolded proteins, a common
phenomenon associated with protein over-expression [50]. To cope with this stress, the ER induces
several mechanisms, including the unfolded protein response (UPR) [51], which in turn can inhibit
protein synthesis, up-regulate the capacity of the cell to fold proteins and also increase the production
of lipids [52]. These newly produced lipids insert into the ER membrane which results in ER expansion
and the decrease in ER stress [53].
Changes in cytokine profiles were also determined as a result of IL2 over-expression. The release
of CX3CL1, CXCL6, IL8, CCL13, CCL15 and CCL20 was significantly decreased (by 1.5 times) in
hADSCs-IL2. These cytokines have been shown to modulate the anti-tumor immune response,
the outcome of which can vary from protection against the cancer to promoting the growth of the
malignancy. For example, CX3CL1 was shown to enhance the antitumor response by activating NK
cells and T-cells [54]. Whilst CCL13 triggers monocytes, T-cells and immature dendritic cells (DCs) to
migrate towards the tumor [55]. However, several cytokines have been shown to promote tumor growth
through increasing angiogenesis, including CXCL6 and IL8 [56,57]. Increased CCL15 and CCL20
expression has been reported in a number of cancers and is associated with a poor prognosis [58–60].
IL6 secretion was high in all hADSCs (20,000–27,000 pg/mL after 72 h), consistent with previous
reports of human adipose tissue-derived MSCs [61]. It has been shown that high levels of IL6
secretion can lead to increased tumor invasion [62], proliferation and resistance to chemotherapy [63].
In particular, high secretion of IL6 in MSCs can activate the IL6/STAT3 signaling pathway and promote
cell invasion in hepatocellular carcinoma cells [62]. Although IL6 secretion after 24 h in all hADSCs was
approximately at the same level, cytokine release was significantly lower at 48 and 72 h in hADSCs-IL2
compared to native hADSCs and hADSCs-BFP. This reduction in IL6 secretion, may allow hADSCs-IL2
to have an inhibitory e↵ect on tumor growth and proliferation compared to native hADSCs. Like IL6,
IL8 secretion was also high in both native and genetically modified hADSCs (9000–11,000 pg/mL)
after 24 h of cultivation. In addition to the fact that MSCs-secreted IL8 can stimulate the proliferation
and angiogenesis of a number of tumors [57,64], this protein is also an important participant of the
epithelial-mesenchymal transition (EMT) of cancer cells [65]. It has been shown that IL8 secreted by
tumor cells undergoing EMT can enhance tumor progression by inducing adjacent epithelial tumor
cells to also undergo EMT [66]. However, it is worth noting that the level of IL8 was significantly
decreased in all hADSCs after 72 h of cultivation (a 5-fold reduction compared to IL8 levels detected at
24 h). In addition, IL8 secretion in hADSCs-IL2 was 2 times lower compared to native hADSCs and
hADSCs-BFP after 72 h of cultivation, which is likely due to overexpression of IL2, but the molecular
mechanisms of this e↵ect require further investigation. TNF-↵ secretion was also found to be higher
(1.5-fold) in hADSCs-IL2 compared to native hADSCs and hADSCs-BFP. TNF-↵ has been shown to
inhibit tumor progression in mice [67]. However, its e↵ect on tumor angiogenesis appear to depend
on cytokine concentration. TNF-↵ is produced in small quantities (pg) by tumor cells and the tumor
microenvironment, and this low level expression is usually associated with poor prognosis [68,69].
Furthermore, TNF-↵ concentrations in the range of 0.5–50 ng/mL, can induce chemotaxis of endothelial
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cells of adrenal capillaries in vitro and cause formation of a branching capillary-like tubular structures.
However, blood vessel formation is abrogated by higher concentrations of TNF-↵ (500 ng/mL) [70].
Therefore, e↵ects of hADSCs-IL2 on tumor growth would depend on the cumulative concentration of
TNF-↵ secreted. The levels of TNF-↵ secreted by hADSCs-IL2 could be considered to be within the
low range and likely to promote the tumorigenic microenvironment. However, these e↵ects would
need to be determined in vivo and per dose of hADSCs-IL2 used.
In addition to changes in cytokine expression, overexpression of IL2 also led to changes in the
expression of a range of other genes, including oncogenes. We found that hADSCs-IL2 also increased
transcription of VEGF, MMP2 and TGF- 1. In confirmation of our findings, previous published studies
have found VEGF expression to be increased by more than 60% in Bcl-2 transfection-modified hypoxic
MSCs and VEGF secretion increased in genetically modified MSCs when cultured in hypoxia [71,72].
We also analyzed the expression level of VEGF, MMP2 and TGF- 1 at the protein level in hADSCs.
Increased expression of VEGF protein in MSCs can be a potential problem, since the secretion level of
this protein in MSCs is high, and it was noted that MSCs can stimulate angiogenesis of a number of
tumors, including pancreatic carcinoma and hepatocellular carcinoma [73,74]. However, the increase in
VEGF gene expression was detected at the mRNA level only, and similar changes in protein expression
were not detected. It remains unclear whether the increases in VEGF gene expression subsequently
translate into changes in VEGF protein levels or whether other mechanisms, such as translation
inhibition and RNA degradation, act to suppress IL2-induced oncogene expression at the protein level.
Whilst VEGF did not show a comparable increase at the protein level, both MMP2 and TGF- 1
showed increased protein translation as well as mRNA transcription. MMP2 and TGF- 1 both play an
important role in EMT of tumor cells [75]. Tumor progression, in particular, tumor metastasis can also
be supported by MMP2, which facilitates tissue penetration by cancer cells [43]. MMP-2 also plays
an important role in regulation of MSCs migration and proliferation [76]. Therefore, the increased
MMP2 expression we detected in hADSCs-IL2 compared to native hADSCs and hADSCs-BFP,
could promote MMP2-mediated migration [77], proliferation [78] and angiogenesis [79]. Interestingly,
TGF- 1 expression was also higher in hADSCs-IL2 as compared to native hADSCs and hADSCs-BFP.
TGF-  plays a dual role in tumor progression acting as both a tumor suppressor and pro-oncogenic
factor [44]. TGF-  also has the ability to stimulate EMT as well as support the mesenchymal phenotype
of tumor cells that have passed through EMT [80,81]. However, as we found increased expression
of TGF- 1 in hADSCs-BFP as well as hADSCs-IL2, increased TGF- 1 may result from any genetic
modification of hADSCs rather than being IL2 specific. The pro or anti-tumor e↵ects of increased
TGF- 1 in hADSCs, regardless of the trigger, remains unclear.
Overall, the expression level of VEGF,MMP2 and TGF- 1was significantly higher in hADSCs-IL2
compared to hADSCs-BFP, suggesting that IL2 expression has an e↵ect on the transcription activity of
these cells. While it is established that increased VEGF andMMP2 expression can stimulate blood
vessel growth and metastases and, thereby, contribute to tumor progression, TGF- 1 can have both,
tumor-suppressing or pro-oncogenic e↵ects [42–44]. In addition, both MMP2 and TGF- 1 proteins as
well as IL6 and IL8, whose secretion levels were high in hADSCs-IL2, are important participants in
EMT of tumor cells. Based on this data, we hypothesize that activation of these tumor promoting genes
and increased expression of MMP2 and TGF- 1 proteins in hADSCs-IL2 could have adverse e↵ects on
tumor growth when used for the treatment of cancer patients and requires additional investigation.
This hypothesiswas somewhat tested by examining the e↵ect ofmolecules secreted by hADSCs-IL2
into CM on tumor cell growth, which were seen to have variable e↵ects on the viability of the cancer
cells. Whilst A549 tumor cells were una↵ected by hADSCs-IL2 CM, the proliferation of SH-SY5Y was
significantly increased, whilst the proliferation of PC3 cells wasmodified both positively and negatively
dependent upon the length of time hADSCs-IL2 had conditioned the media. The ability of IL2 to
inhibit the proliferation of PC3 cells has been reported in the investigation where the combination of
IL2 with trichosanthin led to a stronger inhibition of cell growth compared to trichosanthin alone [82].
Interestingly, cancer cell proliferation in fresh DMEM/F12 was higher compared to cells cultured in
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CM with the exception of SH-SY5Y cells grown in hADSC CM harvested after 72 h of conditioning.
This reduced proliferation of PC3 and A549 cells in CM compared to DMEM/F12 could be explained
by depletion of the nutrients within media during hADSCs culture, although we cannot rule out the
build-up of byproducts that inhibit cell growth. In turn, the stimulation of SH-SY5Y proliferation
after cultivation in hADSC CM is consistent with previous investigations which describe how the
hADSC secretome can stimulate proliferation and promote survival of SH-SY5Y cells by secreting
neuroprotective factors such as brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic
factor (GDNF), beta-nerve growth factor ( -NGF) and insulin-like growth factor-1 (IGF-1) [83,84].
However, when comparing the e↵ect of CM and physical co-culture of the tumor cells with modified
hADSCs, the proliferation of SH-SY5Y cells was significantly decreased (over 20%) after co-culture with
hADSCs-IL2 on plastic compared with control co-cultures. A slight increase in the number of apoptotic
and necrotic SH-SY5Y cells was also found when co-cultured on plastic with hADSCs-IL2 as compared
to native hADSCs, but not hADSCs-BFP, which suggests that hADSCs-IL2 itself did not induce the
death of neuroblastoma cells and their antitumor e↵ect was due to the ability to suppress SH-SY5Y
cell proliferation. In order to evaluate the interaction of hADSCs-IL2 with neuroblastoma cells and
confirm the ability of hADSCs-IL2 to suppress SH-SY5Y proliferation in co-culture, we decided to
culture tumor cells and hADSCs on a thin layer of Matrigel matrix (BD Biosciences, San Jose, CA, USA),
which is rich in extracellular matrix (ECM) components and allows three-dimensional cell culture to
be simulated [85]. Matrigel is a useful tool for studying tumor cell growth and their interaction with
other types of cells of TME, as far as cancer cell cultures on Matrigel are characterized by multicellular
three-dimensional growth and altered cell morphology, proliferation and di↵erentiation [86,87]. It has
been previously reported that hMSCs form capillary-like structures on Matrigel [88], while SH-SY5Y
cells represent the morphology they have when cultured on plastic [89]. We used Matrigel to evaluate
the interaction of SH-SY5Y cells and hADSCs in co-culture. After 48 h, the cells organized into
individual cellular aggregates with flying saucer-like architecture, in which the core consisted of
hADSCs that were surrounded by flat aureoles of SH-SY5Y cells. Tumor cells were actively proliferating
around the stem cell core, the size of individual aggregates was rapidly increasing, which ultimately
led to their fusion. At the same time, hADSCs were proliferating slowly, and the core size remained
unchanged. The same organization of SH-SY5Y and human bone marrow-derived MSCs has been
shown previously [90]. It was interesting that the proliferation rate of tumor cells in co-culture with
hADSCs-IL2 was significantly lower in the first 72 h, compared with native hADSCs and hADSCs-BFP.
However, when the individual aggregates reached large sizes, the SH-SY5Y cell proliferation rate had
increased. We think that this is due to the fact that the proliferation of tumor cells distant from the
nucleus was no longer controlled by stem cells, which suppressed their proliferation by direct contact.
Previously reported data also shows that IL2 can directly inhibit cancer cell growth in vivo
and in vitro. For example, IL2 was shown to directly inhibit the growth of melanoma cells [91].
Local therapy with IL2 and human lymphokine-activated killer (LAK) cells also significantly reduced
the growth of tumors in a nude mouse model of human squamous-cell carcinoma of the head and
neck [92]. The e cacy of IL2 in neuroblastoma therapy has also been investigated. Intratumoral
injection of human fibroblasts genetically modified to express IL2 showed a significant therapeutic
e↵ect with reduced growth or complete eradication of tumors in mice with Neuro-2A neuroblastoma,
which was associated with extensive leukocyte infiltration [93]. In clinical trials the use of IL2 can
result in controversial e↵ects in the combined immunotherapy [94,95]. For example, addition of
subcutaneous IL-2 to immunotherapy with chimeric anti-GD2 monoclonal antibody dinutuximab beta
did not improved outcomes in patients with high-risk neuroblastoma [94]. Another clinical trial has
demonstrated significantly improved outcomes in patients with high-risk neuroblastoma after the
combined treatment with ch14.18 antibody to isotretinoin and IL2 or granulocyte macrophage-colony
stimulating factor (GM-CSF) [95]. The diverse e↵ects of CM harvested from hADSCs-IL2 versus direct
co-culture with hADSCs-IL2 on proliferation of SH-SY5Y could be explained by the level of biologically
active molecules in CM generated by a large number of hADSCs-IL2 cells (compared to the number of
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hADSCs-IL2 cells in co-culture) or by direct cell-cell inhibitory e↵ects of hADSCs-IL2 due to changes
in surface protein expression or other cellular factors altered by IL2 overexpression on SH-SY5Y
in co-culture. It remains to be fully elucidated why hADSCs-IL2 CM increases the proliferation of
SH-SY5Y tumor cells, yet the physical presence of hADSCs-IL2 in co-culture has a negative e↵ect
on tumor cell viability. Taken together, the data from assays using CM and co-culture, support both
paracrine pro-actions and potentially negative direct cell-cell mechanisms occurring.
IL2 plays a critical role in immune system activation that could provide a useful way to stimulate
anti-tumor immune response [96]. To determine hADSCs-IL2 immunogenic e↵ects on leukocyte
surface marker expression, human PBMCs were analyzed for a number of activated T cell and NK
cell markers.
De novo expression of the HLA-DR marker is characteristic of the late-activated (3–5 days)
T-cells [45]. It has been established that endogenous IL2 can increase the expression of HLA-DR
on CD3+ T-cells in vitro [46]. Increased expression of the late-activated T-cell marker HLA-DR in
PBMCs cultured in the CM from hADSCs-IL2 as compared to native hADSC CM was demonstrated.
This suggests that hADSCs-IL2 can a↵ect lymphocyte activation, increasing the population of the late
activated T cells. High HLA-DR expression on T-cells from breast cancer patients correlates with
a good response to neoadjuvant chemotherapy treatment (NACT) [97]. Therefore, hADSCs-IL2 could
be considered a useful addition in combination with chemotherapy.
Significantly large numbers of leukocytes expressing CD38, the CTL activationmarker, were found
in PBMCs cultured in hADSCs-IL2 CM compared to that from native hADSCs. CD38 expression is
associated with late (1 day) activation and proliferation of cytotoxic CD8+ T lymphocytes (CTLs) [45,48].
Activation of CTLs is essential for antitumor defense as they are the key leukocytes mediating cancer
cell death [98].
CD25 is a marker of an early (12 h) activation of T-cells [46]. It was shown that the recombinant
IL2 treatment could increase CD25 expression on T-cells in a dose dependent manner in vitro [99].
However, expression of the early-activated T cell marker CD25 was lower in PBMCs cultured in the
hADSCs-IL2 CM as compared to native hADSC CM. However, we may have been limited in our ability
to detect changes in expression of this early T-cell activation marker, since we were measuring CD25 at
a late time point (after 72 h in culture).
NK cell populations which express NCAM (CD56) in the absence of CD3 can be divided into two
populations: CD56dim and CD56bright NK cells [49]. CD56dim NK cells are cytotoxic and commonly
found in peripheral blood, while CD56bright cells are located in the lymph nodes and play a regulatory
role, secreting IFN-  [100]. NK cells can be activated by IL2 and gain tumor-cell killing capacity [101].
Furthermore, Dubois et al. have shown that IL15 can increase the number of CD56dim and CD56bright
NK cells as well as potentiate the cytotoxic capacity of CD56bright cells [102]. NK cell number was
increased in PBMCs cultured in hADSCs-IL2 CM, with the majority of cells expressing CD56bright
receptor. A high level of tumor infiltrating NK cells is often associated with increased cancer patient
survival in periampullary adenocarcinoma, colorectal carcinoma and gastric carcinoma [103–105].
The CD56bright NK cell population has been shown to be predominant among patients within breast,
melanoma, colon cancer and non-small cell lung cancer, having pro-angiogenic e↵ects and, thereby,
promoting tumorigenesis [106,107]. However, stimulation with endogenous ILs can increase the
number of CD56bright NK cells as well as potentiate the cytotoxic capacity of CD56bright cells [102].
Therefore, MSC-based delivery of IL2 to tumor sites may increase the number of tumor infiltrating NK
cells and increase overall survival of some patients.
In addition to NK cells, increased NKT-leukocyte populations expressing CD3/CD56 were found
in PBMCs cultured in hADSCs-IL2 CM. NKT-cells are cytotoxic against tumors, where killing capacity
is independent of the T-cell receptor activation [47]. Other studies have also reported that NKT-cell
proliferation is IL2-dependent [108,109]. For example, breast cancer cells expressing IL2 were shown
to cause the expansion of NKT-cells in vitro [108]. Furthermore, IL2-secreting fibroblasts were shown
to increase the NKT-cell counts in patients with peripheral neuroectodermal tumor and, subsequently
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tumor cell death [109]. High numbers of CD3+CD56+ NKT cells correlate with the long-term survival
of patients with lung and colorectal cancer [110].
In conclusion, although the IL2 genetically modified hADSCs retain MSC properties, they can
reduce SH-SY5Y cell proliferation and activate humanPBMCs. The IL2 expression-mediated therapeutic
e↵ect of hADSCs may be o↵set by an increased expression of oncogenes, as well as the innate ability
of hADSCs to support tumor growth and suppress T-cell proliferation. Therefore, the potential
tumor-promoting e↵ects of hADSCs-IL2 requires additional investigation in a range of di↵erent cancer
contexts before preclinical application.
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